

## Refining the regulatory context of controlled human infection models

17<sup>th</sup> of October, 2025, Start time 9:30- End time 17:00 (CET)

DRAFT VERSION

### Agenda

Time	Topic	Who	Document / comments
09:30	1. Opening: Introduction into Inno4VAC Introduction into C diff and RSV models and issues encountered along the way	TBD	
10.00	2. Presentation of initial results of Inno4VAC trials RSV en C. diff	Anne fleur Hensen Victor Cnossen	
10.30	3. Keynote speaker: "To use a CHIM, yes or no?"	Anna Durbin	
11.00	4. BREAK		
11.30	5. Role of CHIM in product development pipeline: vision from industry	GSK	
12.00	6. Role of CHIM in product development pipeline: vision from industry	Sanofi	
12.30	7. LUNCH BREAK		
13.30	8. Framework for ethical review from CCMO perspective		
14.00-17.00	9. Panel discussion on prepared statements, statements and questions below  Include break halfway through	Ethicists panel, participants to be confirmed  Panel of stakeholders:  - Meta Roestenber - Ingrid de Visser - Representatives from GSK, Sanofi, regulators	

--	--	--	--	--